摘要
造血干细胞移植(HSCT)是恶性血液病的有效乃至根治方法。在全球同胞全合供者匮乏的背景之下,非血缘供者(URD)移植与亲缘单倍体供者移植(haplo-HSCT)技术进展极大,至今已可完全替代同胞全合移植。haploHSCT结束了供者来源缺乏的时代,其疗效与其他类型供者移植接近,除了恶性血液病,还被开创性地成功用于再生障碍性贫血的治疗;非体外去T细胞模式被成功用于高加索人群。
Allogeneic hematopoietic stem cell transplantation （HSCT） is an effective method to cure hematologic malignan- cies. Under the global background of donor shortage, HSCT with unrelated donors （URD-HSCT） or related haploidentical donors （Haplo-HSCT） has been developing so rapidly that they could now replace the transplantation from identical siblings with similar efficacy and tolerance. The application of Haplo-HSCT terminated the era of donor shortage. It succeeded in treatment of not only hematologic malignancies but also aplastic anemia. The advantage of Haplo-HSCT without ex vivo T cell depletion was further proved and it could be applied in Caucasian population.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2014年第2期101-105,共5页
Chinese Journal of Practical Internal Medicine
